Recruiting

Testing a new imaging scan to find cancer spread

Plain-English translation of NCT05394259 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Read our Pancreatic Cancer research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new imaging scan called PYLARIFY that may help doctors detect cancer that has spread to other parts of the body. The scan uses a radioactive tracer injected into your vein to highlight cancer cells. Researchers want to see if this medication is more accurate than standard imaging tests for finding metastatic cancer in pancreatic, liver, and breast cancer patients.

Current imaging tests sometimes miss small areas of cancer spread, which can affect treatment decisions. This trial exists to see if the new treatment can help doctors find all areas of cancer more reliably, potentially improving care and outcomes.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with pancreatic cancer, liver cancer, or breast cancer that may have spread
your doctor suspects or has confirmed that your cancer may have spread to other parts of your body
you have at least one measurable tumor on recent imaging scans
you are willing and able to undergo a biopsy if needed as part of standard care
your general health is good enough to participate, with an expected life expectancy of at least 3 months

You likely don't qualify if…

you are pregnant or breastfeeding
you have had a previous allergic reaction to similar PET imaging agents
you have had chemotherapy, immunotherapy, or radiation within the past 4 weeks
you are unable to lie flat or tolerate PET-CT imaging
you have a psychiatric condition or social situation that would prevent you from following study requirements

What participation looks like

You will receive an injection of the study medication through your vein, which takes about 5 seconds. You will then undergo a PET-CT imaging scan to see how the medication highlights any cancer in your body. The scan results will be compared to standard imaging tests and any biopsy results to determine how accurate the new medication is at finding cancer spread. Your participation may also involve follow-up imaging or biopsy procedures that are part of your regular cancer care.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

United States

MD Anderson Cancer Center, Houston, Texas